Heart failure & cardiomyopathies
Predictors of Bleeding Events in Acute Decompensated Heart Failure Patients with Antithrombotic Therapy: AURORA Study
Authors' conclusion
High doses of oral loop diuretics, IVC dilatation, and anaemia were predictors of bleeding events in patients hospitalized with ADHF patients. In addition, bleeding events were associated with HF re-hospitalizations.
Study context
- Population
- Acute decompensated heart failure (ADHF) patients on antithrombotic therapy, AURORA registry, January 2015–December 20201,660 screened
- Participants
- 231 patients
- Exposure
- Bleeding vs non-bleeding patients
- Bleedingn = 32
- Outcome
- Predictors of bleeding events (BARC type 2 to 5)
- Follow-up
- Median 651 (IQR 357-1139) days
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
Bleeding events · median follow-up 651 days
Hazard ratio (95% CI)P value
Furosemide equivalent dose ≥0.66 mg/kg
2.64(1.26–5.68)
P = 0.01Haemoglobin ≤10.3 g/dL
2.43(1.14–5.03)
P = 0.02IVC diameter ≥21 mm
2.79(1.16–6.29)
P = 0.02- Bleeding events
- 32 patients (13.8%)
Observational data: associations, not effects.
Further findings
Bleeding site
- Gastrointestinal
- n = 21, 65.6%
- Cerebral
- n = 4, 12.5%
- Intraarticular
- n = 2, 6.3%
- Urogenital
- n = 2, 6.3%
- Haemorrhagic pericardial effusion
- n = 1, 3.1%
- Subcutaneous hematoma
- n = 1, 3.1%
- Haemothorax
- n = 1, 3.1%
Heart failure (HF) re-hospitalization (Kaplan-Meier)
- Higher in bleeding than non-bleeding group
- P = 0.04
Baseline differences, bleeding vs non-bleeding
- Lower haemoglobin
- P < 0.01
- Higher proportion inferior vena cava (IVC) diameter ≥21 mm
- P < 0.01
- Higher furosemide equivalent dose per kg
- P < 0.01
Original publication
Predictors of Bleeding Events in Acute Decompensated Heart Failure Patients with Antithrombotic Therapy: AURORA Study. ESC Heart Fail. Published 30 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →